Small-molecule inhibitors of FGFR, integrins and FAK selectively decrease L1CAM-stimulated glioblastoma cell motility and proliferation

被引:30
作者
Anderson, Hannah J. [1 ]
Galileo, Deni S. [1 ,2 ]
机构
[1] Univ Delaware, Dept Biol Sci, Newark, DE 19716 USA
[2] Christiana Care Hlth Syst, Helen F Graham Canc Ctr & Res Inst, Newark, DE 19713 USA
基金
美国国家卫生研究院;
关键词
L1CAM; L1; Focal adhesion kinase; Fibroblast growth factor receptor; Glioblastoma; FOCAL ADHESION KINASE; IMMUNOGLOBULIN-LIKE DOMAIN; TUMOR-GROWTH; IN-VITRO; L1; GLIOMA; MIGRATION; EXPRESSION; BINDING; CANCER;
D O I
10.1007/s13402-016-0267-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The cell adhesion/recognition protein L1CAM (L1; CD171) has previously been shown to act through integrin, focal adhesion kinase (FAK) and fibroblast growth factor receptor (FGFR) signaling pathways to increase the motility and proliferation of glioblastoma cells in an autocrine/paracrine manner. Here, we investigated the effects of clinically relevant small-molecule inhibitors of the integrin, FAK and FGFR signaling pathways on glioblastoma-derived cells to determine their effectiveness and selectivity for diminishing L1-mediated stimulation. The effects of the FGFR inhibitor PD173074, the FAK inhibitors PF431396 and Y15 and the alpha v beta 3/alpha v beta 5 integrin inhibitor cilengitide were assessed in L1-positive and L1-negative variants of the human glioblastoma-derived cell lines T98G and U-118 MG. Their motility and proliferation were quantified using time-lapse microscopy and DNA content/cell cycle analyses, respectively. The application of all four inhibitors resulted in reductions in L1-mediated motility and proliferation rates of L1-positive glioblastoma-derived cells, down to the level of L1-negative cells when used at nanomolar concentrations, whereas no or much smaller reductions in these rates were obtained in L1-negative cells. In addition, we found that single inhibitor treatment resulted in maximum effects (i.e., combinations of FAK or integrin inhibitors with the FGFR inhibitor were rarely more effective). These results suggest that FAK may act as a point of convergence between the integrin and FGFR signaling pathways stimulated by L1 in these cells. We here show for the first time that small-molecule inhibitors of FGFR, integrins and FAK effectively and selectively abolish L1-stimulated migration and proliferation of glioblastoma-derived cells. Our results suggest that these inhibitors have the potential to reduce the aggressiveness of high-grade gliomas expressing L1.
引用
收藏
页码:229 / 242
页数:14
相关论文
共 64 条
[21]   L 1 adhesion molecule (CD 171) in development and progression of human malignant melanoma [J].
Fogel, M ;
Mechtersheimer, S ;
Huszar, M ;
Smirnov, A ;
Abu-Dahi, A ;
Tilgen, W ;
Reichrath, J ;
Georg, T ;
Altevogt, P ;
Gutwein, P .
CANCER LETTERS, 2003, 189 (02) :237-247
[22]   Automated time-lapse microscopy and high-resolution tracking of cell migration [J].
Fotos, Joseph S. ;
Patel, Vivek P. ;
Karin, Norman J. ;
Temburni, Murali K. ;
Koh, John T. ;
Galileo, Deni S. .
CYTOTECHNOLOGY, 2006, 51 (01) :7-19
[23]   Malignant astrocytic glioma: genetics, biology, and paths to treatment [J].
Furnari, Frank B. ;
Fenton, Tim ;
Bachoo, Robert M. ;
Mukasa, Akitake ;
Stommel, Jayne M. ;
Stegh, Alexander ;
Hahn, William C. ;
Ligon, Keith L. ;
Louis, David N. ;
Brennan, Cameron ;
Chin, Lynda ;
DePinho, Ronald A. ;
Cavenee, Webster K. .
GENES & DEVELOPMENT, 2007, 21 (21) :2683-2710
[24]   L1, a novel target of β-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers [J].
Gavert, N ;
Conacci-Sorrell, M ;
Gast, D ;
Schneider, A ;
Altevogt, P ;
Brabletz, T ;
Ben-Ze'ev, A .
JOURNAL OF CELL BIOLOGY, 2005, 168 (04) :633-642
[25]   Targeting FAK in human cancer: from finding to first clinical trials [J].
Golubovskaya, Vita M. .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2014, 19 :687-706
[26]   Pharmacologic Blockade of FAK Autophosphorylation Decreases Human Glioblastoma Tumor Growth and Synergizes with Temozolomide [J].
Golubovskaya, Vita M. ;
Huang, Grace ;
Ho, Baotran ;
Yemma, Michael ;
Morrison, Carl D. ;
Lee, Jisook ;
Eliceiri, Brian P. ;
Cance, William G. .
MOLECULAR CANCER THERAPEUTICS, 2013, 12 (02) :162-172
[27]   A Small Molecule Inhibitor, 1,2,4,5-Benzenetetraamine Tetrahydrochloride, Targeting the Y397 Site of Focal Adhesion Kinase Decreases Tumor Growth [J].
Golubovskaya, Vita M. ;
Nyberg, Carl ;
Zheng, Min ;
Kweh, Frederick ;
Magis, Andrew ;
Ostrov, David ;
Cance, William G. .
JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (23) :7405-7416
[28]   ADAM10-mediated cleavage of L1 adhesion molecule at the cell surface and in released membrane vesicles [J].
Gutwein, P ;
Mechtersheimer, S ;
Riedle, S ;
Stoeck, A ;
Gast, D ;
Joumaa, S ;
Zentgraf, H ;
Fogel, M ;
Altevogt, P .
FASEB JOURNAL, 2002, 16 (14) :292-+
[29]   Structural Characterization of Proline-rich Tyrosine Kinase 2 (PYK2) Reveals a Unique (DFG-out) Conformation and Enables Inhibitor Design [J].
Han, Seungil ;
Mistry, Anil ;
Chang, Jeanne S. ;
Cunningham, David ;
Griffor, Matt ;
Bonnette, Peter C. ;
Wang, Hong ;
Chrunyk, Boris A. ;
Aspnes, Gary E. ;
Walker, Daniel P. ;
Brosius, Arthur D. ;
Buckbinder, Leonard .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (19) :13193-13201
[30]   DIFFERENTIAL INHIBITION OF NEURON NEURON, NEURON ASTROCYTE AND ASTROCYTE ASTROCYTE ADHESION BY L1, L2 AND N-CAM ANTIBODIES [J].
KEILHAUER, G ;
FAISSNER, A ;
SCHACHNER, M .
NATURE, 1985, 316 (6030) :728-730